Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
Friday, July 26, 2024 BiopharmaWatch Research 1 min read
Key Takeaway: Cognition Therapeutics will host an investor webcast on July 29, 2024, at 8:30 am ET. The event will focus on the results from the Phase 2 SHINE study of CT1812, which targets Mild-to-Moderate Alzheimer’s Disease. This webcast aims to provide insights into the drug's efficacy and potential impact.
Price reaction · baseline $2.1 (2024-07-25 close) · hit pre-market · 6 other CGTX headline(s) in the window, move may be shared
day 0 close
+12.9%
day 1
-36.7%
day 3 · peak
-52.4%
Market Sentiment Analysis
POSITIVE FACTORS
Cognition Therapeutics is actively engaging with investors.
The webcast will discuss results from a significant Phase 2 study.
CT1812 shows promise in treating Mild-to-Moderate Alzheimer’s Disease.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
Frequently Asked Questions
What is the purpose of the investor webcast?
The webcast will discuss the results from the Phase 2 SHINE study of CT1812.
When will the webcast take place?
The investor webcast is scheduled for July 29, 2024, at 8:30 am ET.
What disease is CT1812 targeting?
CT1812 is aimed at treating Mild-to-Moderate Alzheimer’s Disease.
Who is hosting the webcast?
Cognition Therapeutics is hosting the investor webcast.